Development of antibodies and chimeric molecules for cancer immunotherapy
TA Waldmann, JC Morris - Advances in immunology, 2006 - Elsevier
Monoclonal antibodies are among the most rapidly expanding class of therapeutics for
cancer treatment. Monoclonal antibodies targeting non‐Hodgkin's lymphoma (NHL), Her‐
2/neu highly expressing metastatic breast cancer, colorectal cancer, acute myelogenous
leukemia, and B‐cell chronic lymphocytic leukemia (CLL) have received FDA approval.
Promising new targets for antibody therapy include cellular growth factor receptors,
mediators of tumor‐driven neo‐angiogenesis, as well as host negative immunoregulatory …
cancer treatment. Monoclonal antibodies targeting non‐Hodgkin's lymphoma (NHL), Her‐
2/neu highly expressing metastatic breast cancer, colorectal cancer, acute myelogenous
leukemia, and B‐cell chronic lymphocytic leukemia (CLL) have received FDA approval.
Promising new targets for antibody therapy include cellular growth factor receptors,
mediators of tumor‐driven neo‐angiogenesis, as well as host negative immunoregulatory …